InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong · Delayed Price · Currency is HKD 52.70
-0.30 (-0.57%)
Sep 10, 2026, 11:45 AM HKT
HKG:3696 Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 135.09 | 56.24 | 85.83 | 51.18 | 30.15 | |
Revenue Growth | 152.02% | -34.48% | 67.71% | 69.77% | - |
Cost of Revenue | 16.29 | 10.39 | 8.26 | 12.61 | 11.04 |
Gross Profit | 118.79 | 45.85 | 77.58 | 38.57 | 19.11 |
Selling, General & Admin | 33.05 | 23.74 | 23.02 | 25.12 | 20.82 |
Research & Development | 95.14 | 81.38 | 91.9 | 97.34 | 78.18 |
Operating Expenses | 128.15 | 105.83 | 114.91 | 122.3 | 99.23 |
Operating Income | -9.36 | -59.99 | -37.33 | -83.73 | -80.12 |
Interest Expense | -0.28 | -0.21 | -0.09 | -0.09 | -0.1 |
Interest & Investment Income | 10.36 | 5.55 | 6.53 | 4.12 | 0.22 |
Currency Exchange Gain (Loss) | -3.17 | -0.26 | 0.47 | -0.12 | -0.57 |
Other Non Operating Income (Expenses) | -299.64 | -302.02 | 8.82 | -133.52 | -138.08 |
EBT Excluding Unusual Items | -302.08 | -356.93 | -21.61 | -213.35 | -218.64 |
Gain (Loss) on Sale of Investments | 2.82 | 2.3 | 0.56 | 0.45 | -1.04 |
Gain (Loss) on Sale of Assets | -0.1 | -0.13 | - | -0.01 | -2.19 |
Other Unusual Items | 2.1 | 2.5 | 4.12 | 1.35 | 0.06 |
Pretax Income | -297.27 | -352.26 | -16.94 | -211.56 | -221.82 |
Income Tax Expense | 0.3 | 0.06 | 0.16 | 0.08 | 0.01 |
Net Income | -297.56 | -352.32 | -17.1 | -211.64 | -221.83 |
Net Income to Common | -297.56 | -352.32 | -17.1 | -211.64 | -221.83 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 327 | 79 | 72 | 68 | 67 |
Shares Outstanding (Diluted) | 327 | 79 | 72 | 68 | 67 |
Shares Change | 325.96% | 9.55% | 6.33% | 0.76% | - |
EPS (Basic) | -0.91 | -4.48 | -0.24 | -3.13 | -3.31 |
EPS (Diluted) | -0.91 | -4.48 | -0.24 | -3.13 | -3.31 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | 36.19 | -79.62 | -58.25 | -32.14 | -58.5 |
Free Cash Flow Per Share | 0.11 | -1.01 | -0.81 | -0.48 | -0.87 |
Gross Margin | 87.94% | 81.52% | 90.38% | 75.36% | 63.39% |
Operating Margin | -6.93% | -106.66% | -43.49% | -163.60% | -265.75% |
Profit Margin | -220.28% | -626.46% | -19.92% | -413.52% | -735.82% |
Free Cash Flow Margin | 26.79% | -141.58% | -67.86% | -62.79% | -194.03% |
EBITDA | -6.38 | -57.29 | -32.86 | -80.59 | -79.43 |
EBITDA Margin | -4.72% | -101.86% | -38.29% | -157.46% | -263.46% |
D&A For EBITDA | 2.98 | 2.7 | 4.47 | 3.14 | 0.69 |
EBIT | -9.36 | -59.99 | -37.33 | -83.73 | -80.12 |
EBIT Margin | -6.93% | -106.66% | -43.49% | -163.60% | -265.75% |